$LQDA

KIRSCH ARTHUR S sold $1.7M of LQDA (indirect holdings)

KIRSCH ARTHUR S sold 30,000 indirectly-held shares of Liquidia Corp (LQDA) at an average of $57.71 ($54.80–$60.22, $1.73M total) across 3 trades over 2026-06-01 to 2026-06-03.

Original reporting
SEC EDGAR · KIRSCH ARTHUR S
Published Jun 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:21 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest information is the disclosed sale size, price range, and post-sale share count (0), which may influence short-term sentiment but does not change operating outlook based on the provided text.

02

Market read

Traders may monitor for follow-on insider activity or correlate with broader news, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

Insider sales can be driven by diversification, tax, or pre-existing personal liquidity needs; the article provides no rationale, so the trading signal should be treated as sentiment-only.

Relevance 6/10Novelty 3/10Timing: filed June 3, 2026, covering sales from June 1 to June 3

Background

This is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by a director via indirect holdings.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia Corp (LQDA) disclosed an insider Form 4 showing director Kirs ch Arthur S sold 30,000 shares indirectly for about $1.73M.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

Form 4 details a completed open-market sale across three trades at $54.80 to $60.22, with holdings after transaction at 0 shares. The disclosure does not include new company fundamentals, guidance, or regulatory/clinical developments.

Market effects

Minimal, as this is a single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Because the director ended with 0 shares and there is no stated 10b5-1 plan, some traders may interpret it as stronger-than-usual negative signaling, even if the filing is still typically low-signal.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure (LQDA).

  • Kirs ch Arthur S

    Director reporting an indirect open-market sale of 30,000 shares across three trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient